Evidence map›Paper›PMID 38498170›Full record

ArticleIntensive care medicine2024

The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections.

Niccolò Buetti, Alexis Tabah, Nour Setti, Stéphane Ruckly, François Barbier, Murat Akova, Abdullah Tarik Aslan, Marc Leone, Matteo Bassetti, Andrew Conway Morris and 11 more

Erratum issuedOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Intensive care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 17 institutions in 13 countries.

Niccolò BuettiInfection Control Program, Geneva University Hospitals and Faculty of Medicine, World Health Organization Collaborating Centre, Geneva, Switzerland. niccolo.buetti@gmail.com.ORCID 0000-0002-8096-1834
Alexis TabahIntensive Care Unit, Redcliffe Hospital, Brisbane, Australia.
Nour SettiIAME UMR 1137, INSERM, Université Paris-Cité, Paris, France.
Stéphane RucklyIAME UMR 1137, INSERM, Université Paris-Cité, Paris, France.
François BarbierMédecine Intensive Réanimation, Centre Hospitalier Régional d'Orléans, 14, Avenue de L'Hôpital, 45000, Orléans, France.
Murat AkovaDepartment of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey.
Abdullah Tarik AslanDepartment of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey.
Marc LeoneDepartment of Anesthesiology and Intensive Care Unit, Hospital Nord, Aix Marseille University, Assistance Publique Hôpitaux Universitaires de Marseille, Marseille, France.
Matteo BassettiInfectious Diseases Clinic, Department of Health Sciences, University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy.
Andrew Conway MorrisDivision of Anaesthesia, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK.
Kostoula ArvanitiIntensive Care Unit, Papageorgiou University Affiliated Hospital, Thessaloníki, Greece.
José-Artur PaivaIntensive Care Medicine Department, Centro Hospitalar Universitário Sao Joao, Porto, Portugal.
Ricard FerrerIntensive Care Department, SODIR-VHIR Research Group, Vall d'Hebron University Hospital, Barcelona, Spain.
Haibo QiuJiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Nanjing Zhongda Hospital, Southeast University, Nanjing, 210009, China.
Giorgia MontrucchioDepartment of Anesthesia, Intensive Care and Emergency, Città della Salute e della Scienza University Hospital, Turin, Italy.
Andrea CortegianiDepartment of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, Palermo, Italy.
Bircan KayaaslanDepartment of Infectious Diseases and Clinical Microbiology, Ankara City Hospital, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Liesbet De BusDepartment of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium.
Jan J De WaeleDepartment of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium.
Jean-François TimsitIAME UMR 1137, INSERM, Université Paris-Cité, Paris, France.ORCID 0000-0002-6063-7383
EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), the European Society of Clinical Microbiology, the Infectious Diseases (ESCMID) Study Group for Infections in Critically Ill Patients (ESGCIP), and the OUTCOMEREA Network
Ghent University Hospital · BEUniversité Claude Bernard Lyon 1 · FRAix-Marseille Université · FRInserm · FRHacettepe University · TRUniversity of Cambridge · GBUniversity of Turin · ITAnkara Yıldırım Beyazıt University · TRAzienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo · ITThe University of Queensland · AUVall d'Hebron Institut de Recerca · ESZhongda Hospital Southeast University · CNCentre hospitalier universitaire d'Orléans · FROspedale Policlinico San Martino · ITPapageorgiou General Hospital · GRQueensland University of Technology · AUUniversidade do Porto · PT

Funding

Medical Research Council MR/V006118/1
6 · The paper itself

Abstract

purposeThe primary objective of this study was to evaluate the associations between centre/country-based factors and two important process and outcome indicators in patients with hospital-acquired bloodstream infections (HABSI).

methodsWe used data on HABSI from the prospective EUROBACT-2 study to evaluate the associations between centre/country factors on a process or an outcome indicator: adequacy of antimicrobial therapy within the first 24 h or 28-day mortality, respectively. Mixed logistical models with clustering by centre identified factors associated with both indicators.

resultsTwo thousand two hundred nine patients from two hundred one intensive care units (ICUs) were included in forty-seven countries. Overall, 51% (n = 1128) of patients received an adequate antimicrobial therapy and the 28-day mortality was 38% (n = 839). The availability of therapeutic drug monitoring (TDM) for aminoglycosides everyday [odds ratio (OR) 1.48, 95% confidence interval (CI) 1.03-2.14] or within a few hours (OR 1.79, 95% CI 1.34-2.38), surveillance cultures for multidrug-resistant organism carriage performed weekly (OR 1.45, 95% CI 1.09-1.93), and increasing Human Development Index (HDI) values were associated with adequate antimicrobial therapy. The presence of intermediate care beds (OR 0.63, 95% CI 0.47-0.84), TDM for aminoglycoside available everyday (OR 0.66, 95% CI 0.44-1.00) or within a few hours (OR 0.51, 95% CI 0.37-0.70), 24/7 consultation of clinical pharmacists (OR 0.67, 95% CI 0.47-0.95), percentage of vancomycin-resistant enterococci (VRE) between 10% and 25% in the ICU (OR 1.67, 95% CI 1.00-2.80), and decreasing HDI values were associated with 28-day mortality.

conclusionCentre/country factors should be targeted for future interventions to improve management strategies and outcome of HABSI in ICU patients.

Indexed as

Critical IllnessCross InfectionIntensive Care UnitsAgedAnti-Bacterial AgentsBacteremiaDrug MonitoringEuropeFemaleHumansMaleMiddle AgedOutcome and Process Assessment, Health CareProspective StudiesAnti-Bacterial AgentsBacteraemiaCentreHospital-acquired bloodstream infectionsOutcome indicatorProcess indicator

Identifiers

PMID38498170
PMCPMC11164726
OpenAlexW4392921717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.